Towards universal influenza vaccines?

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 366, Issue 1579, 2011, Pages 2766-2773

  Osterhaus, Ab ^a   Fouchier, Ron ^a   Rimmelzwaan, Guus ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Influenza; Seasonal flu vaccines; Universal flu vaccines

Indexed keywords

COST-BENEFIT ANALYSIS; DRUG DEVELOPMENT; EGG; EPIDEMIC; GENETIC ANALYSIS; INFLUENZA; NUMERICAL MODEL; PERFORMANCE ASSESSMENT; POULTRY; PROTEIN; SEASONALITY; VACCINATION; VACCINE;

FLU VACCINE;

EID: 80052441837     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2011.0102     Document Type: Review

References (48)

1. De Jong, J. C., Rimmelzwaan, G. F., Fouchier, R. A. & Osterhaus, A. D. 2000 Influenza virus: a master of metamorphosis. J. Infect. 40, 218-228. (doi:10.1053/jinf. 2000.0652)
2. de Jong, J. C., Beyer, W. E., Palache, A. M., Rimmelzwaan, G. F. & Osterhaus, A. D. 2000 Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 61, 94-99. (doi:10. 1002/(SICI)1096-9071(200005)61:1,94::AID-JMV15. 3.0.CO;2-C)
3. Fiore, A. E., Bridges, C. B. & Cox, N. J. 2009 Seasonal influenza vaccines. Curr. Top. Microbiol. Immunol. 333, 43-82. (doi:10.1007/978-3-540-92165-3_3)
4. Domenech, J., Dauphin, G., Rushton, J., McGrane, J., Lubroth, J., Tripodi, A., Gilbert, J. & Sims, L. D. 2009 Experiences with vaccination in countries endemically infected with highly pathogenic avian influenza: the Food and Agriculture Organization perspective. Rev. Sci. Tech. 28, 293-305.
5. Lu, H., Ismail, M. M., Khan, O. A., Al Hammad, Y., Abdel Rhman, S. S. & Al-Blowi, M. H. 2010 Epidemic outbreaks, diagnostics, and control measures of the H5N1 highly pathogenic avian influenza in the Kingdom of Saudi Arabia, 2007-08. Avian Dis. 54(Suppl. 1), 350-356. (doi:10.1637/8807-040109-ResNote.1)
6. Nishiguchi, A., Yamamoto, T., Tsutsui, T., Sugizaki, T., Mase, M., Tsukamoto, K., Ito, T. & Terakado, N. 2005 Control of an outbreak of highly pathogenic avian influenza, caused by the virus sub-type H5N1, in Japan in 2004. Rev. Sci. Tech. 24, 933-944.
7. Pfeiffer, J., Suarez, D. L., Sarmento, L., To, T. L., Nguyen, T. & Pantin-Jackwood, M. J. 2010 Efficacy of commercial vaccines in protecting chickens and ducks against H5N1 highly pathogenic avian influenza viruses from Vietnam. Avian Dis. 54(Suppl. 1), 262-271. (doi:10.1637/8715-031909-Reg.1)
8. Soares Magalhaes, R. J., Pfeiffer, D. U. & Otte, J. 2010 Evaluating the control of HPAIV H5N1 in Vietnam: virus transmission within infected flocks reported before and after vaccination. BMC Vet. Res. 6, 31. (doi:10.1186/1746-6148-6-31)
9. Stegeman, A., Bouma, A. & de Jong, M. C. 2010 Use of epidemiologic models in the control of highly pathogenic avian influenza. Avian Dis. 54(Suppl. 1), 707-712. (doi:10.1637/8821-040209-Review.1)
10. White, N. J., Webster, R. G., Govorkova, E. A. & Uyeki, T. M. 2009 What is the optimal therapy for patients with H5N1 influenza? PLoS Med. 6, e1000091. (doi:10.1371/ journal.pmed.1000091)
11. Russell, C. A. et al. 2008 Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 26(Suppl. 4), D31-D34. (doi:10.1016/j.vaccine.2008.07.078)
12. Russell, C. A. et al. 2008 The global circulation of seasonal influenza A (H3N2) viruses. Science 320, 340-346. (doi:10.1126/science.1154137)
13. Frey, S., Poland, G., Percell, S. & Podda, A. 2003 Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a nonadjuvanted influenza vaccine in non-elderly adults. Vaccine 21, 4234-4237. (doi:10.1016/S0264-410X(03)00456-0)
14. Vesikari, T., Groth, N., Karvonen, A., Borkowski, A. & Pellegrini, M. 2009 MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27, 6291-6295. (doi:10.1016/j.vaccine.2009.02.004)
15. Vesikari, T., Pellegrini, M., Karvonen, A., Groth, N., Borkowski, A., O'Hagan, D. T. & Podda, A. 2009 Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28, 563-571. (doi:10.1097/INF.0b013e318 19d6394)
16. Bodewes, R., Rimmelzwaan, G. F. & Osterhaus, A. D. 2010 Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev. Vaccines 9, 59-72.(doi:10.1586/erv.09.148)
17. World Health Organization 2011 Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. See http://www.who.int/csr/disease/avian_influenza/country/cases_table_2011_02_25/en/index.html (updated 25 February 2011).
18. Garten, R. J. et al. 2009 Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325, 197-201. (doi:10. 1126/science.1176225)
19. Wood, J. M. 2002 Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 20(Suppl. 5), B40-B44. (doi:10.1016/S0264-410X(02)00509-1)
20. Smith, D. J., Lapedes, A. S., de Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. & Fouchier, R. A. M. 2004 Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371-376. (doi:10.1126/science.1097211)
21. Keawcharoen, J., Spronken, M. I., Vuong, O., Bestebroer, T. M., Munster, V. J., Osterhaus, A. D., Rimmelzwaan, G. F. & Fouchier, R. A. M. 2010 Repository of Eurasian influenza A virus hemagglutinin and neuraminidase reverse genetics vectors and recombinant viruses. Vaccine 28, 5803-5809. (doi:10.1016/j.vaccine. 2010.06.072)
22. Bosch, B. J. et al. 2010 Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 84, 10 366-10 374. (doi:10.1128/JVI.01035-10)
23. Steel, J., Lowen, A. C., Wang, T. T., Yondola, M., Gao, Q., Haye, K., Garcia-Sastre, A. & Palese, P. 2010 Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. 1, e00018. (doi:10.1128/mBio. 00018-10)
24. Wang, T. T. et al. 2010 Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl Acad. Sci. USA 107, 18979-18984. (doi:10.1073/pnas.1013387107)
25. Wei, C. J. et al. 2010 Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064. (doi:10.1126/science.1192517)
26. Schotsaert, M., De Filette, M., Fiers, W. & Saelens, X. 2009 Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert. Rev. Vaccines 8, 499-508. (doi:10.1586/erv.09.6)
27. Rimmelzwaan, G. F., Kreijtz, J. H., Bodewes, R., Fouchier, R. A. & Osterhaus, A. D. 2009 Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 27, 6363-6365. (doi:10.1016/j.vaccine.2009.01.016)
28. Rimmelzwaan, G. F., Fouchier, R. A. & Osterhaus, A. D. 2007 Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18, 529-536. (doi:10. 1016/j.copbio.2007.11.002)
29. Kreijtz, J. H., Bodewes, R., van Amerongen, G., Kuiken, T., Fouchier, R. A., Osterhaus, A. D. & Rimmelzwaan, G. F. 2007 Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25, 612-620. (doi:10.1016/j.vaccine.2006.08.036)
30. Kreijtz, J. H. et al. 2009 Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 27, 6296-6299. (doi:10.1016/j.vaccine.2009.03.020)
31. Kreijtz, J. H., de Mutsert, G., van Baalen, C. A., Fouchier, R. A., Osterhaus, A. D. & Rimmelzwaan, G. F. 2008 Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J. Virol. 82, 5161-5166. (doi:10.1128/JVI.02694-07)
32. Bodewes, R. et al. 2009 Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS ONE. 4, e5538. (doi:10.1371/journal.pone.0005538)
33. Bodewes, R. et al. 2011 Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J. Virol. 85, 2695-2702.(doi:10. 1128/JVI.02371-10)
34. 8+ T-cell responses in mice. J. Gen. Virol. 91, 1743-1753. (doi:10. 1099/vir.0.020784-0)
35. Cowling, B. J. et al. 2010 Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin. Infect. Dis. 51, 1370-1379. (doi:10.1086/657311)
36. Janjua, N. Z. et al. 2010 Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: first detection of the association in British Columbia, Canada. Clin. Infect. Dis. 51, 1017-1027. (doi:10. 1086/656586)
37. Skowronski, D. M. et al. 2010 Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS Med. 7, e1000258. (doi:10.1371/journal.pmed.1000258)
38. van den Brand, J. M. et al. 2011 Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J. Virol. 85, 2851-2858. (doi:10.1128/JVI. 01939-10)
39. Del Giudice, G., Stittelaar, K. J., van Amerongen, G., Simon, J., Osterhaus, A. D., Stohr, K. & Rappuoli, R. 2009 Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci. Transl Med. 1, 12re1.
40. Zarocostas, J. 2011 WHO backs further probes into possible link between H1N1 vaccine and narcolepsy in children. Br. Med. J. 342, d909. (doi:10.1136/bmj.d909)
41. Montastruc, J. L., Durrieu, G. & Rascol, O. 2011 Pandemrix, (H1N1)v influenza and reported cases of narcolepsy. Vaccine 29, 2010. (doi:10.1016/j.vaccine. 2010.12.092)
42. European Medicines Agency 2011 European Medicines Agency reviews further data on narcolepsy and possible association with Pandemrix. Press release 18 February 2011. See http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/02/news_detail_001211.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp&jsenabled=true.
43. 8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 18, 623-632. (doi:10.1016/S0264-410X(99)00278-9)
44. Kreijtz, J. H. et al. 2009 MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS ONE 4, e7790. (doi:10.1371/journal.pone. 0007790)
45. Kreijtz, J. H. et al. 2009 Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J. Infect. Dis. 199, 405-413. (doi:10.1086/595984)
46. Kreijtz, J. H. et al. 2007 Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 195, 1598-1606. (doi:10.1086/517614)
47. Kreijtz, J. H. et al. 2010 Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J. Gen. Virol. 91, 2745-2752. (doi:10.1099/vir.0.024885-0)
48. 8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP + M1. Clin. Infect. Dis. 52, 1-7. (doi:10.1093/cid/ciq015)